Immunohistochemical Study of Androgen Receptor Expression in Estrogen Receptor-Negative Invasive Breast Carcinoma and its Relation with Clinicopathologic Factors by Abdelaal, Shereen E. et al.
Open Access Maced J Med Sci. 2020 Sep 10; 8(A):615-622. 615
Scientific Foundation SPIROSKI, Skopje, Republic of Macedonia
Open Access Macedonian Journal of Medical Sciences. 2020 Sep 10; 8(A):615-622.
https://doi.org/10.3889/oamjms.2020.5321
eISSN: 1857-9655
Category: A - Basic Sciences
Section: Pathology
Immunohistochemical Study of Androgen Receptor Expression 
in Estrogen Receptor-Negative Invasive Breast Carcinoma and its 
Relation with Clinicopathologic Factors
Shereen E. Abdelaal1*, Samia M. Gabal2, Amina A. Gamal el Din1, Hala N. Hosni2, Hafiza A. Sharaf1
1Department of Pathology, National Research Centre, Giza, Egypt; 2Department of Pathology, Faculty of Medicine, Cairo 
University, Cairo, Egypt
Abstract
BACKGROUND: Estrogen receptor (ER)-negative breast carcinomas lack the expression of ER and they have 
no targeted hormone therapies. The androgen receptor (AR) is a newly emerge biomarker. Detecting AR in these 
tumors may provide a target for future therapies.
AIM: The aim of the study is to examine the immunohistochemical expression profiles of AR protein in ER-negative 
invasive breast carcinomas and to assess the relation between AR expression and the clinicopathologic factors 
such as age, tumor size, tumor grade, tumor type, immunohistochemical type, lymph node status, and Ki67 
expression.
METHODS: Sixty paraffin blocks of ER-negative invasive breast carcinoma cases were stained immunohistochemically 
by AR. Positive expression was defined as ≥1% nuclear staining.
RESULTS: AR positivity was detected in 55% of the studied cases. The positive cases were scored by H-score with 
a median=117, and a range of 3–285 and by Allred score with a median=7, and a range of 3-8. AR is expressed in 
60.9% of triple-negative breast carcinoma cases. AR expression was higher in older age, and there were significant 
positive correlations between the degree of AR expression (AR%, AR intensity, and H-score) and age (p=0.050, 
0.007, 0.033, respectively). There was non-significant negative correlation between Ki67% and the degree of AR 
expression (AR%, AR intensity, H-score, and Allred score). Regarding different histological types, tumor grade, tumor 
size, lymph node status, and immunohistochemical types, there was no significant difference between AR positive 
and AR negative cases.
CONCLUSION: AR is frequently expressed in ER-negative invasive breast carcinoma; especially in older age, 
and in a large number of triple-negative subtypes. This may give chance to benefit from future AR target therapy. 
We recommend further research work on AR expression in the special histologic subtypes of ER-negative breast 
carcinoma and in the triple negative group.
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Introduction
Breast cancer is the most common cancer in 
females and a leading cause of death [1]. In Egypt, 
breast cancer proved to be the commonest cancer 
in females accounting for 32.04% of all malignant 
tumors [2]. Gene-DNA wise, breast cancer is subdivided 
into: Luminal A, luminal B, normal-like, basal-like, and 
human epidermal growth factor receptor-2 (HER-2) 
overexpression categories [3]. Another subtyping 
for breast cancer includes: One subtype expressing 
estrogen receptor (ER-positive) tumors and another 
subtype non-expressing (ER-negative) tumors [4]. 
ER-negative tumors accounted for 25–30% of breast 
carcinomas. Unfortunately, they have fewer strategies 
for therapy in comparison to ER-positive tumors [5]. 
ER-negative tumor group includes triple-negative 
tumors being negative for ER, progesterone receptor 
(PR) and HER2 and tumors which are positive for 
HER-2. They are not subjected for antiestrogenic 
therapy and the triple-negative tumors lack any 
specific targeted therapy [6]. Thus, an ultimate goal for 
research in the field of breast cancer is to find more 
biomarkers as potential targets for therapy [7]. The 
androgen receptor (AR) is a newly emerge biomarker. 
About 70–80% of breast carcinomas show AR; which 
being a steroid hormone is highly similar to ER and PR, 
structure wise, and function wise. The role of ER/PR is 
wellestablished with respect to therapy and prognosis 
of breast carcinoma. However, the importance of 
detection of AR in breast carcinoma is still unclear [8]. 
Therefore, the aim of this study is to examine the 
immunohistochemical expression profiles of AR protein 
in ER-negative invasive breast carcinomas for the 
possible use of AR as a target therapy and to assess 
the relationship between AR expression and the 
clinicopathologic prognostic factors such as age, tumor 
size, tumor grade, tumor type, immunohistochemical 
type, lymph node status, and Ki67 expression (as a 
proliferation marker).
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Materials and Methods
In this retrospective cross-sectional study, 
a total of 60 paraffin blocks of ER-negative invasive 
breast carcinoma cases, with known receptor status 
(ER, PR, and Her2), were retrieved from the Pathology 
Department at Kasr El-Aini Hospitals, Cairo University. 
The clinicopathological parameters such as age, tumor 
size, tumor grade, tumor histological type, and lymph 
node status, were retrieved from the patient’s pathology 
reports. The cases were anonymous as an ethical 
requirement. The Medical Research Ethics Committee 
of National Research Centre, Cairo, Egypt, approved 
the study (No. 12067).
Three sections of 4 µm thickness were 
cut from each block; one section was stained with 
hematoxylin and eosin to establish the diagnosis. The 
tumors were histologically graded according to Elston-
Ellis modification of Scarff-Bloom-Richardson grading 
system [9]. The histological types were determined 
according to the fifth edition of the WHO classification 
of invasive breast carcinoma [10]. Tumor staging was 
based on TNM classification according to American 
Joint Committee on Cancer, 8th edition [11]. The other 
two sections were mounted on positively charged glass 
slides for immunohistochemical staining by AR and 
Ki67.
 Immunohistochemical staining for AR 
was done using AR Rabbit Monoclonal Antibody 
(SP107, 200R-16, 1.0 ml, concentrate, 1: 50 dilution, 
Cell Marque, USA). Heat-induced epitope retrieval 
technique was used applying Cell Marque’s Trilogy 
together with a pressure cooker permitting simultaneous 
deparaffinization, rehydration, and epitope retrieval. 
The used detection system was Econo Tek HRP Anti-
Polyvalent (DAB), Ready-to-Use (ScyTek Laboratories, 
U.S.A). Known prostatic carcinoma sections were used 
as a positive control. In the negative control, 1% bovine 
serum albumin was used in place of the primary 
antibody.
The primary Rabbit Polyclonal anti-Ki-67 
Antibody (RB-9043-P; 1.0 ml, 1: 50 dilution, Thermo 
Fisher Scientific, Fremont, USA) was used for Ki67 
immunohistochemical staining.
Semi-automated evaluation of AR and Ki67 
was performed using the digital light microscope 
(Leica DM 3000, LED) of the Leica Qwin Image 
Analyzer system (V3,5,1-LEICA Imaging Systems Ltd, 
Cambridge, England,), at the Pathology Department in 
the National Research Centre.
In all cases, AR immunoreactivity was assessed 
as the percentage of positive cells. We considered nuclear 
immunopositivity of ≥1% of malignant cells as the cutoff 
point for positivity, according to the American Society of 
Clinical Oncology (ASCO) and the College of American 
Pathologists (CAP) guidelines and recommendations 
for immunohistochemical interpretation of hormone 
receptors in breast cancer [12].
Two scoring systems were used for AR 
expression scoring; H-score method [7], and Allred 
Score system [13]. In H-Score system, the score was 
given as the percentage of the immunopositive nuclei 
(0–100%) multiplied by a value corresponding to 
level of intensity (0 none, 1 weak, 2 moderate, and 3 
strong). The score result ranged between 0 (no staining 
in the tumor) and 300 (diffuse strong staining of the 
tumor). In Allred score intensity and proportion score 
were applied. Intensity score was the one used in H 
score (0–3). The proportion score applied counted the 
percentage of the immunopositive nuclei; categorizing 
them into six subgroups (0, no staining; 1, <1%; 2, 
between 1% and 10%; 3, between 11% and 33%; 
4, between 34% and 66%; and 5, between 67% and 
100% of the cells staining). A total score was obtained 
by adding the proportion score and intensity score. The 
total score was graded on a scale from 0 to 8, where 
Allred score of 0, 2 indicated a negative result, while 
cutoff to positivity was three or more.
The immunohistochemical analysis of Ki67 
was performed following recommendations from the 
International Ki67 in Breast Cancer Working Group. The 
entire section was scanned at low-power magnification 
(×100) to determine areas with the highest numbers 
of positive nuclei (hot spots) within the tumor tissue. 
Only nuclear staining is considered positive. Staining 
intensity is not relevant. Ki67 proliferative index 
assessment was expressed as the percentage of ki67-
positive cells within the total number of malignant cells 
among five high-power fields (×400) .A percentage of 
15% or more was considered to be a cutoff point [14].
Statistics
The collected data were coded, tabulated, 
and statistically analyzed using Statistical Package 
for the Social Sciences (SPSS) program, software 
version 18.0.
Descriptive statistics were done for quantitative 
data; as minimum and maximum of the range as well 
as mean±SD (standard deviation) for quantitative 
parametric data, and as median, 1st and 3rd inter-quartile 
range for quantitative non-parametric data. It was done 
for qualitative data as number and percentage. The 
analyses were done for quantitative variables using 
independent t-test in cases of two independent groups 
with parametric data. In qualitative data, analyses for 
independent variables were done using Chi-square 
test for differences between proportions and Fisher’s 
exact test for variables with small expected numbers, 
while correlations were done using spearman test for 
numerical non-parametric and qualitative data.
The level of significance was taken at p ≤ 0.05 
is significant, otherwise is non-significant.
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Results
In the studied cases, the age ranged between 
25 and 71 years with a mean age of 49.3 years ± 12.7. 
The studied cases consisted of 45 cases of invasive 
ductal carcinoma (Figure 1), eight cases of invasive 
lobular carcinoma (Figure 2), four cases of medullary 
carcinoma (Figure 3), one case of mucinous carcinoma 
(Figure 4), one case of secretory carcinoma, and one 
case of tubular carcinoma. The cases were subdivided 
Table 2: Tumor specimens and mass size distribution among 
the studied cases
Tumor specimens n = 60, n (%)
Mass 39 (65.0)
Core biopsy (pTX) 21 (35.5)
Mass size n = 39, n (%)
pT1 5 (12.8)
pT2 18 (46.2)
pT3 14 (35.9)
pT4 2 (5.1)
into two immunohistochemical types; HER-2 positive 
tumors type (ER-negative, PR-negative, and HER2-
positive) and the triple negative (TN) tumors type 
(ER-negative, PR-negative, and HER2-negative). The 
majority of the cases were Grade II (73.3%), followed 
by Grade III (26.7%). The distribution of histological 
types, immunohistochemical types, and tumor grade 
among the studied cases are represented in Table 1.
Table 1: Distribution of histological types, immunohistochemical 
types and tumour grade among the studied cases
Pathologic features n = 60, n (%)
Histological types
Ductal carcinoma 45 (75)
Lobular carcinoma 8 (13.3)
Medullary carcinoma 4 (6.7)
Mucinous carcinoma 1 (1.7)
Secretory carcinoma 1 (1.7)
Tubular carcinoma 1 (1.7)
Immunohistochemical types:
Triple negative 23 (38.3)
HER2 positive 37 (61.7)
Tumour grade
Grade II 44(73.3)
Grade III 16(26.7)
The tumor specimens consisted of 21 specimens 
of core biopsies and 39 specimens of mass biopsies 
(lumpectomy or modified radical mastectomy). The 
size distribution among the mass biopsies is shown in 
Table 2. In the studied cases, the lymph node statuses 
were known in modified radical mastectomy cases and 
unknown in lumpectomy and core biopsy cases. The 
lymph node status distribution among the studied cases 
is represented in Table 3.
AR positivity was detected in 33 cases (55%) 
out of the sixty studied cases. Twenty-eight cases 
Figure 1: Invasive ductal carcinoma, showing sheets and clusters 
of malignant ductal epithelial cells with moderate anaplasia and 
pleomorphism, together with moderate attempts at ductal formation 
(Grade II), (H and E, ×400)
Figure 2: Invasive breast lobular carcinoma showing, small uniform 
tumor cells arranged in single file (Indian file) pattern (H and E, ×400)
Figure 3: Breast medullary carcinoma, showing syncytial sheets 
of large tumor cells, highly pleomorphic with indistinct cell borders 
and prominent nucleoli. The surrounding stroma shows dense 
lymphoplasmacytic infiltrate (H and E, ×400)
Figure 4: Breast mucinous carcinoma showing clusters of malignant 
epithelial cells floating within pools of extracellular mucin (H and E, 
×400)
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HER2-positive tumors and in 60.9% among TN tumors. In 
spite of a high percentage of AR expression in TN tumor 
cases, the p value was not statistically significant. There 
was no significant difference between AR positive and AR 
Table 3: Lymph node status distribution among the studied 
cases
Status n = 60, n (%)
Known 29 (48.3)
Unknown (pNX) 31 (51.7)
Lymph node status distribution n=29, n (%)
pN0 5 (27.6)
pN1 18 (34.5)
pN2 14 (20.7)
pN3 2 (17.2)
(46.7%) had ≥10% of tumor cell nuclei staining positive 
for AR, five cases (8.3%) had <10% of tumor cell nuclei 
staining positive for AR, and 27 cases (45%) were AR 
negative (<1% positivity). The characteristics of AR 
positive cases (Intensity, AR %, H-score, and Allred 
score) are shown in details in Table 4.
Table 4: Characteristics of AR positive cases
Intensity n = 33 %
Mild 10.0 30.3
Moderate 4.0 12.1
Strong 19.0 57.6
Degree of positivity Median (IQR) Range
AR % 41.0 (19.0–9.0) 2.0–95.0
H-score 117.0 (19.0–207.0) 3.0–285.0
Allred score 7.0 (4.5–8.0) 3.0–8.0
IQR: Interquartile range.
The mean age of AR positive cases was 51 ± 11.7 
years; while the mean age of AR negative cases was 
47.1 ± 13.7. AR expression was non-significantly higher 
in older age; higher AR expression (57.6% of AR positive 
cases) was noted in patients aged above 50 years (Table 5).
Table 5: Comparison between AR positive and negative cases 
regarding age
Types AR positive (n = 33) AR negative (n = 27) p-value
Age (years) 51.1 ± 11.7 47.1 ± 13.7 #0.230
Age
≤50 (years) 14 (42.4%) 14 (51.9%) ^0.708
˃50 (years) 19 (57.6%) 13 (48.1%)
#Independant t-test, ^Chi square test.
The AR expression in different histological types 
was variable (Figures 5-8), 55.6% of invasive ductal 
carcinomas and 75% of invasive lobular carcinomas were 
positive for AR, while all medullary carcinomas cases were 
negative for AR. AR expression was higher within Grade 
II tumor cases (61.4%). AR was expressed in 51.4% of 
Figure 5: Invasive ductal carcinoma, showing strong AR staining 
and high percentage of expression (92%). H score=276 and Allred 
score=8 (Immunoperoxidase, ×200)
Figure 7: Breast lobular carcinoma, showing strong AR staining 
and high percentage of expression (70%). H score=210 and Allred 
score=8 (Immunoperoxidase, ×200)
Figure 6: Invasive ductal carcinoma, showing strong AR staining 
and high percentage of expression (68%). H score=204 and Allred 
score=8 (Immunoperoxidase, ×400)
Figure 8: Mucinous carcinoma breast, showing strong AR staining 
and high percentage of expression (90%). H score=270 and Allred 
score=8 (Immunoperoxidase, ×400)
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negative cases regarding Ki67 expression. The relationship 
between AR expression and the histopathological 
parameters is shown in details in (Table 6).
Table 6: Comparison between AR positive and negative cases 
regarding histopathological parameters
Histopathological 
parameters
Total 
number (n)
AR positive cases: 
n (%)
AR negative 
cases: n (%)
p-value
Tumour grade
Grade II 44 27 (61.4) 17 (38.6) ^0.100
Grade III 16 6 (37.5) 10 (62.5)
Tumour size
PT1 5 2 (40) 3 (60) 1.000#
PT2 18 8 (44.4) 10 (55.6)
PT3 14 7 (50) 7 (50)
PT4 2 1 (50) 1 (50)
Lymph node status
PN0 8 5 (62.5) 3 (37.5) 0.846#
PN1 10 4 (40) 6 (60)
PN2 6 3 (50) 3 (50)
PN3 5 2 (40) 3 (60)
Tumour histological 
types
Ductal 45 25 (55.6) 20 (44.4) #0.083
Lobular 8 6 (75) 2 (25)
Medullary 4 0 (0.0) 4 (100)
Other special types* 3 2 (66.7),  
(mucinous, tubular)
1 (33.3), 
(secretory)
Immunohistochemical types
HER2 positive 37 19 (51.4) 18 (48.6) ^0.471
TN 23 14 (60.9) 9 (39.1)
Ki67 expression
Ki67 ≥ 15% 42 23 (54.8) 19 (45.2) ^0.955
Ki67 < 15% 18 10 (55.6) 8 (44.4)
#Fisher Exact test, ^Chi square test, Data expressed as (n, %), *other special types (mucinous, tubular and 
secretory carcinoma), TN: Triple negative.
Spearman correlation was done between the 
degree of AR expression (AR %, AR intensity, H-score, 
and Allred score) and variables such as age, HER2 
expression, tumor size, lymph node status, and Ki67 
expression (Table 7). There was significant positive 
correlation between the degree of AR expression 
(AR%, AR intensity, and H-score) and age (Figure 9). 
There was non-significant negative correlation between 
Ki67% and the degree of AR expression (AR%, AR 
intensity, H-score, and Allred score) (Figure 10).
Table 7: Correlation between degree of AR positivity expression 
and other variables
Variable Measure AR % AR intensity H-score Allred score
Age r 0.341 0.463 0.372 0.299
p 0.050* 0.007* 0.033* 0.091
N 33 33 33 33
HER2 expression r 0.242 0.045 0.178 0.085
p 0.175 0.804 0.322 0.637
N 33 33 33 33
Tumor size r −0.083 −0.060 −0.083 0.004
p 0.742 0.812 0.742 0.987
N 18 18 18 18
LN status r 0.403 0.312 0.385 0.292
p 0.153 0.277 0.174 0.311
N 14 14 14 14
Ki67% expression r −0.209 −0.331 −0.208 −0.140
p 0.244 0.060 0.245 0.436
N 33 33 33 33
Correlations are within AR positive cases r: Spearman correlation, *Significant.
Discussion
In the current study, AR positivity was detected 
in 33 cases (55%) out of the sixty studied cases with 
a median of 41% of AR nuclear immunoreactivity 
(range 2–95%). Twenty-eight cases (46.7%) had ≥10% 
of tumor cell nuclei staining positive for AR, and five 
cases (8.3%) had <10% of tumor cell nuclei staining 
positive for AR. Twenty-seven cases (45%) were AR 
negative (<1% positivity). These results were nearly 
similar to the results of Micello et al. [15]; who observed 
AR positivity in one hundred and 28 cases (56.6%), 
having 59% as average AR immunostaining within 
nuclei (range 10–100%). Among those, 48.8% of cases 
showed >10% positive cells, while 7.8% cases showed 
<10% cells with positive staining within nuclei, and 
43.4% of the cases were negative for AR negative.
Figure 10: Correlation between Ki67 expression and AR intensity
Our results were also nearly in agreement 
with the study of Park et al. [16], who mentioned that 
the AR positive immunoreactivity was observed in 50% 
(65 of 130) of cases negative for ER. Furthermore, in 
the study of Hu et al. [17], the positivity for AR was 
noticed in 42.9% among 303 cases of women with 
tumors negative for ER, and it was 44% in the study 
of Collins et al. [18]. The study of Yu et al. [19] showed 
that AR immunohistochemical staining was found in 
53.2% (58/109) of cases negative for ER, while Qi et 
al. [20] showed that AR immunoreactivity was found 
in 65% (248 out of 383 cases) of tumors negative for 
ER.
The cutoff value for positivity for hormone 
receptor was considered as staining of 10% or 
more nuclei in the tumor. To allow largest number of 
Figure 9:Correlation between degree of AR expression and age
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patients to benefit from therapy antagonizing the 
hormone estrogen, the ASCO mentioned the cutoff 
value for positivity for hormone receptor to be 1% of 
stained cells instead of 10% [21]. We used 1% as the 
minimum staining required for AR positivity; similar to 
the most recent ASCO/CAP guidelines for evaluation 
of hormone receptors and similar to the most recent 
studies of [21], [22], [23], [12]. Meanwhile, other studies 
had used the 10% as the minimum requirement for a 
positive interpretation [15], [19]. Tumors having 1–9% 
IHC immunoreactivity showed controversies regarding 
their category as being considered immunopositive or 
immunonegative; and subsequently as to whether or 
not to use endocrine therapy [13]. According to the most 
recent ASCO/CAP guidelines update for evaluation of 
hormone receptors, these category should be reported 
as low positive [12]. Hence, in this study, we subdivided 
the positive cases into two categories, one had <10% 
positivity and the other had 10% or more.
 In our study, raising the minimum threshold 
for AR immunopositivity from ≥1% to ≥10% could result 
in losing 8.3% of all cases positive for AR, and 8.7% 
of TN breast carcinoma (TNBC) cases positive for AR. 
In Safarpour et al. [24] study, elevating the minimum 
threshold for AR immunopositivity from ≥1% to ≥10% 
would result in losing 4.6% of all cases positive for AR, 
and 22% of TNBC cases positive for AR. Subsequently, 
this group of cases would lose their chance for benefiting 
from therapy targeting hormone in the future.
 For scoring of AR positive cases, we used 
two scoring systems. The first one was the H-score 
with a median =117, and a score range of 3–285. The 
second one was the Allred score with a median =7, and 
a range of 3–8. Niemeier et al. [7] also used H-score for 
scoring of AR immunohistochemical expression, having 
a median score =150, and a score range = 15–300. 
However, Yu et al. [19] assessed AR expression using 
Allred score.
Cohen et al. [25] mentioned that the H-score 
details the percentage of cells showing none, weak, 
moderate, or strong staining; thus giving a wide dynamic 
range (0–300). On the other hand, the Allred score is 
obtained from summation of scores of proportion and 
intensity, thus giving a limited dynamic range (0–8). 
Hence, theoretically speaking, H-score can provide 
clinicians with more information regarding prognosis. 
That is why some institutes prefer to use H Score. 
However, Brouckaert et al. [13] mentioned that for the 
time being, Allred score is the most established one 
and that a good cutoff to predict benefit from treatment 
targeting hormones is an Allred score of ≥3.
In the current study, AR positivity was seen 
in the two ER-negative immunohistochemical types 
(according to expression of Her2). In HER2 positive 
type, AR positivity was detected in 51.4% (19 cases 
out of 37). In TN type, AR positivity was detected 
in 60.9% (14 cases out of 23). This was consistent 
with the results of Collins et al. [18], in which AR 
immunopositivity was detected in 58.7% of invasive 
carcinomas of the breast; positive for Her2. It was also 
in agreement with the study of Qi et al. [20], where AR 
positivity was observed in 55% of TNBCs. However, 
this was in contrast to the study of Niemeier et al. [7], in 
which AR immunopositivity was seen in 10% (3/30) of 
the triple-negative breast carcinomas. These variable 
percentages of AR immunopositivity in different studies 
among TNBCs may be attributed to the heterogeneity 
of the TN category; being molecularly classified into 
seven subtypes among which is the luminal AR (LAR) 
subtype (ER-, PR-, and AR+) showing highest AR 
immunohistochemical expression and the other TN 
tumor subtypes (non-LAR) which may express AR but 
at a low immunohistochemical expression.
 In this study, the frequency of AR 
immunohistochemical expression varied according 
to histologic type of invasive breast carcinoma. AR 
expression was seen in 55.6% of invasive ductal 
carcinomas (NST) and 75% of invasive lobular 
carcinomas. The cases of both mucinous carcinomas 
and tubular carcinomas were positive for AR. Medullary 
and secretory carcinomas were negative for AR. This was 
similar to the study of Micello et al. [15], which showed 
56.6% of AR positivity in invasive duct carcinomas 
negative for ER. This also agreed with the study of 
Collins et al. [18], in which AR expression was seen in 
the majority of tumor histopathologic types negative for 
ER as follows: 71.0% of duct carcinoma cases, 96.3% of 
lobular carcinoma cases, 80.5% of mucinous carcinoma 
cases, and 100% of tubular carcinoma cases. Similarly, 
the previous study showed that AR expression was 
seen in 73.6% of invasive duct carcinoma cases, 83.3% 
of invasive lobular carcinoma cases, 41.7% of mucinous 
carcinoma cases, 25% of medullary carcinoma cases, 
and 100% of tubular carcinoma cases. This was nearly 
consistent with our result, except for differences in 
medullary and mucinous carcinomas. This difference 
may be due to the different number of cases of each 
type included in each study [16].
 In our study, age was non-significantly higher 
in cases positive for AR (mean, 51 years) than cases 
negative for AR (mean, 47 years). In AR positive cases, 
patients older than 50 years represented 57.6% while 
patients younger than 50 years represented 42.4%. 
However, there was no significant difference by Chi-
square test (p = 0.708). On the other hand, Spearman 
correlation showed significant positive correlations 
between the degree of AR immunohistochemical 
expression (AR % (r = 0.341, p = 0.050), AR intensity 
(r = 0.463, p = 0.007), and H-score (r = 0.372, p = 0.033) 
and age. This was nearly similar to the result of Pistelli 
et al. [26], where AR positive cases with age higher than 
50 years accounted for 60% while patients younger 
than 50 years accounted for 40% of AR immunopositive 
cases; however, there was no significant difference 
(p = 0.9). This also was in agreement with McGhan et 
al. [27], where AR immunohistochemical expression 
was associated with older age of the patients as 
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compared to tumors that were negative for AR 
expression. On the other hand, in Park et al. [16] 
study, there were no significant differences between 
AR immunohistochemical expression and age at the 
time of diagnosis. This contradiction may be due to the 
difference in the cutoff values of age used, as they used 
35 years as a cutoff value for age grouping, while we 
used 50 years as a cutoff value.
 Our results demonstrated a negative correlation 
between Ki67% and the degree of AR expression (AR % 
(r = – 0.209; p = 0.244), AR intensity (r = – 0.331; 
p = 0.060), H-score (r = –208; p = 0.245), and Allred score 
(r = – 0.140; p = 0.436), but it was non-significant. This 
was nearly consistent with the results of Sutton et al. [22], 
where the AR expression levels showed a negative 
correlation with Ki67 expression in the AR-positive 
tumors, and it was significant (r = –0.55; p = 0.0006). 
They supposed that the negative correlation may be 
related to the anti-proliferative effect of AR stimulation 
and these findings further support the idea that high AR 
levels may be associated with a better prognosis in some 
previous studies. This was also consistent with the results 
of Pistelli et al. [26], where positive AR immunostaining 
was inversely correlated with a higher Ki67.
 In the current study, there was no significant 
difference between AR positive and AR negative cases 
regarding tumor size, tumor grade, HER-2 status, 
and lymph node status. These results were similar to 
the results that were mentioned by Yu et al. [19] who 
showed that AR immunohistochemical expression had 
no relation to the parameters, such as tumor size, lymph 
node status, histological grade, and HER-2 status. On 
the contrary Park et al. [16] mentioned that, AR showed 
significant immunohistochemical expression in patients 
with smaller tumor size (p = 0.035) and lower histologic 
grade (p < 0.001); the difference may be attributed to 
the larger number of cases used by them; giving more 
chance to reveal such clinicopathologic association.
We may conclude that AR is frequently 
expressed in estrogen-negative invasive breast 
carcinoma (55% positivity); especially in older age. AR is 
variably expressed in different histologic types of breast 
cancer, except in medullary and secretory carcinomas. 
AR is expressed in a large number of triple-negative 
breast cancers (60.9%) which indicates that AR could 
be a new target for therapy in this difficult to treat entity. 
AR positive breast carcinoma is more commonly noticed 
in older patients as the degree of AR expression has 
a significant positive correlation with higher age. There 
was a non-significant negative correlation between 
Ki67% and the degree of AR expression. There is no 
significant difference between AR positive and AR 
negative cases regarding tumor grade, tumor size, tumor 
immunohistochemical type, and lymph node status.
One important possible implication of this study 
is the future use of AR-related targeted therapy for 
breast cancer, especially for ER-negative/AR-positive 
tumors. We recommend further research work on AR 
in the special histological types of ER-negative breast 
carcinoma and in the TN group; using larger sample 
size. This may give more chance to investigate whether 
those tumors can be amenable to future AR target 
therapy.
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